Mark R. Albertella

机构：AstraZeneca (United Kingdom), AstraZeneca (Singapore), Abzena (United Kingdom) · ORCID：0000-0003-4406-6135

发表论文 197 篇 · 总被引 3017 次 · h-index 19

代表论文

• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer (2026 · Nature · 被引 6)
• Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair (2025 · NAR Cancer · 被引 6)
• Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells (2025 · Nucleic Acids Research · 被引 4)
• Abstract 254: The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement in vitro , in vivo and in the clinic. (2026 · Cancer Research)
• Abstract 7172: Combination of B7-H4-TOP1i ADC, PD-1/TIGIT bispecific antibody, and PARP inhibition orchestrates angiogenesis suppression and interferon-program activation in a syngeneic mouse model (2026 · Cancer Research)
• Abstract 4683: Loss of nuclear integrity at persistent DNA bridges ties PARP inhibitors to cGAS/STING signaling (2026 · Cancer Research)